# Semaglutide Dosage Protocol Guide 2026: Reconstitution, Weekly Escalation & Vial Math for GLP-1 Research
> Research Use Only (RUO) Disclaimer: This guide is intended for educational and research purposes only. Semaglutide is an FDA-approved prescription medication (Ozempic® NDA 209637; Wegovy® NDA 215256). All dosing schedules referenced here are drawn from published peer-reviewed clinical trial literature and FDA-approved prescribing information. This is not medical advice. Do not use this information to self-administer any substance. Research use only.
---
Semaglutide is the most studied GLP-1 receptor agonist in the world, with a clinical trial database spanning hundreds of thousands of subjects. For researchers working with lyophilized semaglutide peptide, that science only translates into valid data if the reconstitution, dosing math, and escalation schedule are executed correctly.
This guide focuses on the practical mechanics: how to reconstitute accurately, how to calculate doses and track vial depletion, and the weekly escalation schedule drawn from the STEP and SUSTAIN clinical programs. For a broader background on semaglutide's mechanism of action, see our Semaglutide Research Guide 2026. For price and supplier comparison, see our Best Semaglutide Research Sources 2026.
---
1. What Is Semaglutide? Research Context
Semaglutide is a 29-amino-acid GLP-1 receptor agonist with 94% structural homology to endogenous GLP-1(7-36) amide. Its half-life of approximately 165–184 hours — enabling once-weekly dosing — comes from three structural modifications:
- •Aib substitution at position 8 — blocks DPP-4 protease degradation
- •C-18 fatty diacid chain via a linker at Lys26 — enables reversible albumin binding, extending circulation
- •Arg34Lys and Lys26Arg substitutions — minimize receptor cross-reactivity
These modifications yield a half-life roughly 10× longer than native GLP-1, making it the benchmark GLP-1 agonist for research comparing metabolic, cardiovascular, and neurological outcomes.
FDA-Approved Formulations
| Product | Indication | Approved Dose Range |
|---|---|---|
| Ozempic® | Type 2 diabetes + CV risk | 0.25 mg → 0.5 mg → 1 mg → 2 mg (weekly) |
| Wegovy® | Chronic weight management | 0.25 mg → 2.4 mg (16-week escalation, weekly) |
| Rybelsus® | Type 2 diabetes | 3 mg → 7 mg → 14 mg (daily, oral) |
Research-grade lyophilized semaglutide is commonly supplied as freeze-dried powder in 2 mg, 5 mg, and 10 mg vials. Unlike commercial pen formulations, these require reconstitution before use.
---
2. Reconstitution Guide: BAC Water, Volumes, and Concentrations
What You Need
- •Lyophilized semaglutide vial (2 mg, 5 mg, or 10 mg)
- •Bacteriostatic water (BAC water) — 0.9% benzyl alcohol; preferred for multi-use vials stored up to 28 days
- •Sterile water for injection — acceptable for single-use or same-day applications only
- •1 mL insulin syringe (U-100, 29–31 gauge needle)
- •Alcohol swabs (70% isopropyl)
- •Refrigerator (2–8°C / 36–46°F) for post-reconstitution storage
- •Permanent marker for vial labeling
Concentration Reference Table
The reconstitution volume determines your working concentration. Choose a target concentration that simplifies your dosing math:
| Vial Size | BAC Water Added | Resulting Concentration | Common Use Case |
|---|---|---|---|
| 2 mg | 1.0 mL | 2.0 mg/mL (2,000 mcg/mL) | Higher-dose protocols |
| 2 mg | 2.0 mL | 1.0 mg/mL (1,000 mcg/mL) | Standard starting concentration |
| 5 mg | 2.5 mL | 2.0 mg/mL | Higher-dose protocols |
| 5 mg | 5.0 mL | 1.0 mg/mL | Standard concentration |
| 10 mg | 5.0 mL | 2.0 mg/mL | Economy vial, higher dose |
| 10 mg | 10.0 mL | 1.0 mg/mL | Economy vial, standard |
Recommendation: For most research escalation protocols, 1.0 mg/mL is the most convenient working concentration — it makes dose-to-volume conversion straightforward (0.25 mg dose = 0.25 mL drawn in a 1 mL syringe).
Step-by-Step Reconstitution Protocol
Step 1 — Inspect the lyophilized vial
Semaglutide lyophilized powder should appear white to off-white. Discard any vial with visible particulates, discoloration, or compromised septum integrity.
Step 2 — Prepare your workspace
Work on a clean surface. Wipe the vial septum with a fresh alcohol swab and allow 30 seconds to fully air-dry before inserting a needle. Never inject through a wet septum (risk of introducing alcohol).
Step 3 — Draw up BAC water
Load your syringe with the target volume of bacteriostatic water. For a 2 mg vial targeting 1.0 mg/mL: draw exactly 2.0 mL (use two 1 mL syringes or a 3 mL syringe).
Step 4 — Inject water down the vial wall
Insert the needle at a slight angle and direct the stream of BAC water down the inner wall of the vial — not directly onto the powder cake. This prevents foaming and minimizes mechanical denaturation of the peptide.
Step 5 — Allow passive dissolution — do NOT shake
Gently roll or swirl the vial between your palms for 30–60 seconds. Allow it to sit at room temperature for 5–10 minutes. The solution should become clear and colorless to faintly yellow.
Step 6 — Inspect before use
A slightly yellowish tint is normal for semaglutide. The solution must be clear with no visible particles or cloudiness. Discard if precipitated, cloudy, or heavily discolored.
Step 7 — Label and refrigerate
Label the vial immediately with: compound name, concentration (e.g., 1.0 mg/mL), reconstitution date, and expiry date (28 days from reconstitution when using BAC water). Store at 2–8°C.
---
3. Weekly Escalation Schedule from Clinical Research
The escalation schedules below are drawn directly from FDA prescribing information and STEP/SUSTAIN clinical protocols. They represent the validated approach used in the peer-reviewed literature.
Ozempic® Escalation (SUSTAIN Program — Diabetes + CV)
| Week | Dose | Volume (at 1 mg/mL) | Notes |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 0.25 mL | Initiation dose — not intended for glycemic control |
| Weeks 5–8 | 0.5 mg | 0.50 mL | Maintenance minimum |
| Week 9+ | 1.0 mg | 1.00 mL | Standard therapeutic dose |
| Optional escalation | 2.0 mg | 1.00 mL at 2 mg/mL | If tolerability allows |
Wegovy® Escalation (STEP Program — Weight Management)
This is the most commonly referenced escalation in weight management research:
| Weeks | Dose | Volume (at 1 mg/mL) | Volume (at 2 mg/mL) |
|---|---|---|---|
| 1–4 | 0.25 mg | 0.25 mL | 0.125 mL |
| 5–8 | 0.5 mg | 0.50 mL | 0.25 mL |
| 9–12 | 1.0 mg | 1.00 mL | 0.50 mL |
| 13–16 | 1.7 mg | 1.70 mL | 0.85 mL |
| 17+ | 2.4 mg | 2.40 mL | 1.20 mL |
> Note: The 0.25 mg initiation dose is a tolerability ramp-up dose, not a pharmacologically active dose for weight management endpoints. Tolerability is the primary outcome being optimized in weeks 1–4. Research designs studying dose-response should account for this distinction when selecting their starting conditions.
Accelerated Escalation Protocols
Some published research uses compressed timelines. For example, STEP 5 (82-week trial) reached maintenance dose at week 16. Researchers designing shorter-duration studies sometimes compress the escalation to 4–8 weeks total. Any compressed escalation protocol should document its deviation from the standard FDA schedule.
---
4. Syringe Measurements and Dose Accuracy
Reading a U-100 Insulin Syringe
A standard U-100 insulin syringe measures volume in units (1 unit = 0.01 mL). The key conversions:
| Units on Syringe | Volume (mL) | Dose at 1.0 mg/mL | Dose at 2.0 mg/mL |
|---|---|---|---|
| 5 units | 0.05 mL | 0.05 mg (50 mcg) | 0.1 mg (100 mcg) |
| 10 units | 0.10 mL | 0.10 mg (100 mcg) | 0.2 mg (200 mcg) |
| 25 units | 0.25 mL | 0.25 mg | 0.5 mg |
| 50 units | 0.50 mL | 0.50 mg | 1.0 mg |
| 100 units | 1.00 mL | 1.00 mg | 2.0 mg |
Practical note: At 1.0 mg/mL, the standard escalation doses (0.25 mg, 0.5 mg, 1.0 mg) fall exactly on the 25-unit, 50-unit, and 100-unit marks. This is why 1.0 mg/mL is the preferred working concentration for most research protocols.
Injection Sites
Three subcutaneous injection sites used in all clinical trials:
1. Abdomen — at least 2 inches from the navel in any direction; most used in STEP/SUSTAIN trials
2. Anterolateral thigh — outer front surface of either thigh
3. Lateral upper arm — requires assistance; less commonly used in research settings
Rotate injection sites within and across these regions to minimize local tissue reactions. Inject into pinched subcutaneous tissue at 45–90°, depending on needle length and tissue depth.
---
5. Vial Depletion Calculator Walkthrough
One of the most common errors in research is miscalculating how many doses remain in a vial, leading to mid-study supply shortages. Here's how to track vial depletion mathematically.
Example: 5 mg Vial for Full Wegovy Protocol
Setup:
- •Vial: 5 mg semaglutide
- •Reconstitution: 5.0 mL BAC water → 1.0 mg/mL
- •Total volume available: 5.0 mL
Wegovy escalation doses per injection:
| Phase | Dose | Volume per injection | Injections in phase | Total volume used |
|---|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 0.25 mL | 4 | 1.00 mL |
| Weeks 5–8 | 0.50 mg | 0.50 mL | 4 | 2.00 mL |
| Weeks 9–12 | 1.00 mg | 1.00 mL | 4 | 4.00 mL |
| Weeks 1–12 total | 12 injections | 7.00 mL |
A single 5 mg vial (5.0 mL at 1 mg/mL) covers weeks 1–8 plus one injection in week 9, leaving a deficit. For a complete 12-week initiation protocol, you need approximately 7 mg total, meaning:
- •Two 5 mg vials (10 mg total, with 3 mg remaining for the maintenance phase), or
- •One 10 mg vial (10 mL at 1 mg/mL — 10 mg capacity, covers 12+ weeks with remainder)
General formula:
> Doses per vial = (Vial size in mg) ÷ (Dose per injection in mg)
For a 5 mg vial at 0.5 mg/dose: 5 ÷ 0.5 = 10 injections (10 weeks at once-weekly).
Use the Peptides.SO Reconstitution Calculator to run vial math automatically for any vial size, concentration, and dose combination.
---
6. Common Reconstitution Mistakes to Avoid
These are the most frequent errors documented in research settings — each can compromise data integrity or peptide viability.
Mistake #1: Shaking the Vial
Why it's harmful: Aggressive shaking causes mechanical shear stress that can denature the peptide and promote aggregation. Aggregated semaglutide will not bind GLP-1 receptors with the same affinity as properly dissolved solution, introducing systematic error into dose-response experiments.
Fix: Gently roll or swirl; never shake.
Mistake #2: Adding Water Directly Onto the Powder
Why it's harmful: Directing the water stream onto the lyophilized cake causes localized foaming and surface denaturation at the air-water interface.
Fix: Aim the stream down the inner vial wall at a low angle.
Mistake #3: Using Regular Sterile Water for Multi-Use Vials
Why it's harmful: Sterile water has no preservative. A multi-use vial opened multiple times over days or weeks risks microbial contamination.
Fix: Use bacteriostatic water (0.9% benzyl alcohol) for any vial reconstituted for multi-use over 28 days.
Mistake #4: Storing at Room Temperature After Reconstitution
Why it's harmful: Reconstituted peptide solutions degrade faster at ambient temperature. Stability data for semaglutide in solution requires refrigeration (2–8°C) to maintain activity over the 28-day post-reconstitution window.
Fix: Refrigerate immediately after reconstitution and label with expiry date.
Mistake #5: Wrong Working Concentration
Why it's harmful: If you calculate doses based on 1.0 mg/mL but actually reconstituted at 2.0 mg/mL, every injection delivers double the intended dose. This is the most dangerous math error in peptide research.
Fix: Label every vial clearly with the exact concentration. Recalculate draw volume if you change the reconstitution volume.
Mistake #6: Starting at Full Therapeutic Dose
Why it's harmful: The 0.25 mg initiation dose in both Ozempic and Wegovy protocols exists specifically because higher starting doses produce significant GI adverse events (nausea, vomiting, diarrhea). Research designs that skip the ramp-up phase risk confounding tolerability with treatment effects.
Fix: Follow the validated escalation schedule unless the research design specifically requires a different starting dose (and documents the rationale).
Mistake #7: Not Accounting for Dead Volume
Why it's harmful: Every syringe has dead volume (residual fluid in the needle hub that cannot be drawn). In 29-gauge insulin syringes, this can be 0.02–0.05 mL per injection — significant when you're tracking precise milligrams across 20+ injections in a vial.
Fix: Use the same syringe type throughout a study; account for dead volume in your vial depletion math by reducing the effective volume available by ~0.02–0.05 mL per draw.
---
7. Storage Requirements
Pre-Reconstitution (Lyophilized Vial)
| Condition | Requirement |
|---|---|
| Temperature | 2–8°C (refrigerated), or up to 25°C for short-term transport |
| Light | Store in original packaging; protect from direct light |
| Moisture | Keep sealed; lyophilized powder is hygroscopic |
| Shelf life | Per manufacturer certificate of analysis (CoA); typically 24+ months from manufacture |
Post-Reconstitution (Solution)
| Condition | Requirement |
|---|---|
| Temperature | 2–8°C (refrigerated); do not freeze |
| Duration | Up to 28 days when reconstituted with bacteriostatic water |
| Duration (sterile water) | Use within 24 hours |
| Light | Avoid prolonged exposure to direct light |
| Signs of degradation | Cloudiness, precipitation, color change beyond pale yellow → discard |
---
8. Linking to the Peptides.SO Calculator Tool
For researchers who want to skip the manual math, the Peptides.SO Reconstitution Calculator handles:
- •Reconstitution concentration — enter vial size and BAC water volume to get concentration
- •Dose-to-volume conversion — enter your target dose and concentration to get the draw volume in mL and insulin syringe units
- •Vial depletion tracking — enter the number of doses planned and see how many vials you need for the full protocol
- •Cost-per-dose calculator — factor in supplier price per vial to compare true research costs
This tool is particularly useful for researchers running multi-week escalation protocols where vial depletion math needs to account for changing dose levels across phases.
---
9. Summary: Semaglutide Research Protocol Quick Reference
| Parameter | Specification |
|---|---|
| Compound class | GLP-1 receptor agonist |
| Half-life | ~165–184 hours (once-weekly dosing) |
| Administration | Subcutaneous injection |
| Common vial sizes | 2 mg, 5 mg, 10 mg (lyophilized) |
| Preferred reconstitution | 1.0 mg/mL with bacteriostatic water |
| Starting dose (Wegovy) | 0.25 mg/week × 4 weeks |
| Maintenance dose | 2.4 mg/week (16-week escalation) |
| Post-reconstitution storage | 2–8°C, up to 28 days (BAC water) |
| Do NOT shake | Gentle swirl or roll only |
---
Related Resources
- •Semaglutide Research Guide 2026: Mechanism, Dosing, Sources & Pricing
- •Semaglutide Dosage Guide: Research Protocol, Reconstitution & Timing
- •Peptide Reconstitution Calculator — Step-by-Step Guide
- •Best Semaglutide Research Sources 2026
- •Tirzepatide Dosage Protocol Guide 2026
- •GLP-1 Receptor Agonists: Complete Research Overview
---
This article is for educational and research purposes only. Semaglutide is an FDA-approved prescription medication. All information is drawn from published clinical trial literature and FDA prescribing information. Not medical advice. Research use only (RUO).